Show simple item record

dc.contributor.authorBarrett, Tristanen
dc.date.accessioned2018-08-29T09:48:11Z
dc.date.available2018-08-29T09:48:11Z
dc.date.issued2018-06-11en
dc.identifier.issn1464-4096
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/279028
dc.description.abstractObjectives: To analyse the detection rates of primary MRI-fusion transperineal prostate biopsy using combined targeted and systematic core distribution in three tertiary referral centres. Patients and Methods: Multicentre, prospective outcome study of 807 consecutive biopsy-naïve patients having undergone MRI-guided transperineal prostate biopsy as the first diagnostic intervention between 10/2012 and 05/2016. MRI was reported following PI-RADS criteria. 236 patients had 18-24 systematic transperineal biopsies only, and 571 patients underwent additional targeted biopsies either by MRI-fusion or cognitive targeting if PI-RADS ≥3 lesions were present. Detection rates for any and Gleason score (GS) 7-10 cancer in targeted and overall biopsy. Predictive values were calculated for different PI-RADS and PSA density (PSA-D) groups. Results: Cancer was detected in 68% and GS 7-10 in 49% of patients. Negative predictive value of 236 PI-RADS 1-2 MRI in combination with PSA-D ≤0.1 ng/ml/cm3 for GS7-10 was 0.91 (±0.07, 8% of study population). In 418 patients with PI-RADS 4-5 lesions using targeted plus systematic biopsies, the cancer detection rate of GS 7-10 was significantly higher at 71% versus 59% and 61% with either approach alone (p=0.000). For 153 PI-RADS 3 lesions, the detection rate was 31% with no significant difference to systematic biopsies with 27% (p>0.05). Limitations include variability of mpMRI reading and Gleason grading. Conclusion: MRI-based transperineal biopsy performed at high volume, tertiary care centres with a significant experience of prostate mpMRI and image-guided targeted biopsies yielded high detection rates of GS 7-10 cancer. Prostate biopsies may not be needed for men with low PSA-D and a non-suspicious MRI. In patients with high probability lesions, combined targeted and systematic biopsies are recommended.
dc.description.sponsorshipRWTH Aachen University, Philips Healthcare Germany Clinical Research Fellowship, Cancer Research UK, National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre, Engineering and Physical Sciences Research Council, Imaging Centre in Cambridge and Manchester, Cambridge Experimental Cancer Medicine Centre, German Research Foundation, Ipsen, Tolmar, Abbvie, AstraZeneca, Siemens Healthcare, MedCom GmbH
dc.languageengen
dc.publisherWiley-Blackwell
dc.subjecttransperinealen
dc.subjectmagnetic resonance imagingen
dc.subjectMRI‐TRUS fusionen
dc.subjectcognitive fusionen
dc.subjectprostate biopsyen
dc.subject#PCSM,en
dc.subject#ProstateCanceren
dc.titleMulticentre evaluation of Magnetic Resonance Imaging sup-ported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.en
dc.typeArticle
prism.endingPage49
prism.issueIdentifier1en
prism.publicationDate2018en
prism.publicationNameBJU Internationalen
prism.startingPage40
prism.volume122en
dc.identifier.doi10.17863/CAM.26404
dcterms.dateAccepted2017-10-11en
rioxxterms.versionofrecord10.1111/bju.14049en
rioxxterms.versionAM*
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2018-06-11en
dc.contributor.orcidBarrett, Tristan [0000-0002-1180-1474]
dc.identifier.eissn1464-410X
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2017-10-11en
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/full/10.1111/bju.14049en
rioxxterms.freetoread.startdate2018-10-11


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record